These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27238057)

  • 1. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy.
    McDonald CM; Meier T; Voit T; Schara U; Straathof CS; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; Rummey C; Leinonen M; Spagnolo P; Buyse GM;
    Neuromuscul Disord; 2016 Aug; 26(8):473-80. PubMed ID: 27238057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.
    Buyse GM; Voit T; Schara U; Straathof CSM; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; McDonald CM; Rummey C; Meier T;
    Lancet; 2015 May; 385(9979):1748-1757. PubMed ID: 25907158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy.
    Buyse GM; Goemans N; van den Hauwe M; Meier T
    Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy.
    Buyse GM; Voit T; Schara U; Straathof CS; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; Rummey C; Leinonen M; Mayer OH; Spagnolo P; Meier T; McDonald CM;
    Pediatr Pulmonol; 2017 Apr; 52(4):508-515. PubMed ID: 27571420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy.
    Mayer OH; Leinonen M; Rummey C; Meier T; Buyse GM;
    J Neuromuscul Dis; 2017; 4(3):189-198. PubMed ID: 28869486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home-Based Monitoring of Pulmonary Function in Patients with Duchenne Muscular Dystroph.
    Buyse GM; Rummey C; Meier T; Leinonen M; Voit T; McDonald CM; Mayer OH
    J Neuromuscul Dis; 2018; 5(4):419-430. PubMed ID: 30282375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial.
    Buyse GM; Goemans N; van den Hauwe M; Thijs D; de Groot IJ; Schara U; Ceulemans B; Meier T; Mertens L
    Neuromuscul Disord; 2011 Jun; 21(6):396-405. PubMed ID: 21435876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy.
    Servais L; Straathof CSM; Schara U; Klein A; Leinonen M; Hasham S; Meier T; De Waele L; Gordish-Dressman H; McDonald CM; Mayer OH; Voit T; Mercuri E; Buyse GM;
    Neuromuscul Disord; 2020 Jan; 30(1):5-16. PubMed ID: 31813614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy.
    Meier T; Rummey C; Leinonen M; Spagnolo P; Mayer OH; Buyse GM;
    Neuromuscul Disord; 2017 Apr; 27(4):307-314. PubMed ID: 28189481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of idebenone in Duchenne muscular dystrophy.
    Mercuri E; Muntoni F
    Lancet; 2015 May; 385(9979):1704-1706. PubMed ID: 25907159
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
    Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
    Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of body habitus and respiratory function in Duchenne muscular dystrophy.
    Chew K; Carey K; Ho G; Mallitt KA; Widger J; Farrar M
    Respir Med; 2016 Oct; 119():35-40. PubMed ID: 27692145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.
    Kim S; Zhu Y; Romitti PA; Fox DJ; Sheehan DW; Valdez R; Matthews D; Barber BJ;
    Neuromuscul Disord; 2017 Aug; 27(8):730-737. PubMed ID: 28645460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy.
    Daftary AS; Crisanti M; Kalra M; Wong B; Amin R
    Pediatrics; 2007 Feb; 119(2):e320-4. PubMed ID: 17272595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidants for Treatment of Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
    Ren S; Yao C; Liu Y; Feng G; Dong X; Gao B; Qian S
    Eur Neurol; 2022; 85(5):377-388. PubMed ID: 35697003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
    Lynch DR; Perlman SL; Meier T
    Arch Neurol; 2010 Aug; 67(8):941-7. PubMed ID: 20697044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posterior spinal fusion for scoliosis in duchenne muscular dystrophy diminishes the rate of respiratory decline.
    Velasco MV; Colin AA; Zurakowski D; Darras BT; Shapiro F
    Spine (Phila Pa 1976); 2007 Feb; 32(4):459-65. PubMed ID: 17304138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapies that are available and under development for Duchenne muscular dystrophy: What about lung function?
    Gogou M; Pavlou E; Haidopoulou K
    Pediatr Pulmonol; 2020 Feb; 55(2):300-315. PubMed ID: 31834673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
    Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.